Home
overview

SMi are delighted to present our 9th annual Asthma & COPD event to be held in Central London on Monday 15th & Tuesday 16th of April 2013. Following on from the great success of our previous Asthma & COPD, and COPD: Novel Therapeutics and Management Strategies events, Asthma & COPD 2013 will continue to bring forward leading industry experts and esteemed academic KOLs in the field to discuss the latest developments and challenges alongside strategies to improve asthma and COPD patient outcomes.

An estimated 65 million people currently suffer from COPD globally with 300 million asthma sufferers. Considering that patients with COPD are often misdiagnosed with asthma due to the understated yet significant similarities between the two conditions, it is increasingly important to support respiratory research in order to phenotype patients for personalized medicine and reduce associated costs for research.

With the global markets for asthma & COPD drugs to hit $47 billion in 2017, Asthma & COPD 2013 will present a uniquely informative platform for those new to the field and for established respiratory professionals alike. This event will also present an ideal opportunity to network with key industry professionals and absorb knowledge from leaders in the fields of asthma and COPD. 
 

Compare and contrast exacerbations of Asthma & COPD
Explore current and novel inhalation devices alongside combination therapies
Establish patient phenotyping, by way of biomarkers for Asthma & COPD, for efficient and effective therapeutic outcomes
Investigate patient reported outcomes (PROs)
Highlight current and novel treatments such as CCR3 antagonists and cytokine modulators/inhibitors
Determine the unmet needs in Asthma & COPD and discuss how these needs can be addressed
Network with key industry professionals and KOLs in Asthma & COPD

 

Professor Peter Barnes, Head of Respiratory Medicine at Imperial College London commented “ I am happy to be involved in this important meeting that provides an update on new treatments for COPD and asthma as this is a key therapeutic area, where several new approaches are in development”

This event is unmissable for Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Research Fellows, Principal Investigators, Managers, Project/Team Leaders in
  • Respiratory Medicine
  • Respiratory Pharmacology
  • Inflammatory Disease
  • Research Immunology
  • Pharmacology
  • Respiratory Licensing
  • Respiratory, Inflammation and Autoimmunity
  • Pulmonary Disease
  • Immunology
  • Respiratory Cell Biology
  • Respiratory Therapeutics
  • Inhalation Devices
  • Medical Devices
  • Inflammation Discovery
  • Respiratory Medicine Regulation

 

 

Attendees at previous SMi Asthma & COPD events include: 3M Healthcare, 4SC, Accovion, Actelion, Actimis, Activaero, Aeropharm, AstraZeneca, Bayer, Bedfont Scientific, Biomedical Systems Europe, Biotie Therapies, Boehringer Ingelheim, CareFusion, Centocor, Chiesi, Deepbreeze, Galapagos, Genentech, GSK, Grunenthal, Laboratorios Almirall, MedImmune, Merck, Mpex, Munidpharma, Napp, Novartis, Nycomed, Pfizer,Revotar, Roche, Sanofi-Aventis, Schering Plough, Sepracor, Synairgen, Topigen, UCB, Vitalograph
 

AlgiPharma AS; Almirall; Asthma Uk; Astrazeneca; AstraZeneca GmbH; Barts & The London NHS Trust; Biomedical Systems Europe; Biopharm Insight; Boehringer Ingelheim; Boehringer-Ingelheim Pharma; Celbo AB; Chiesi Farmaceutici S. P. A. ; Decision Resources; ElectroCore Medical, AB; European Medicines Agency (E M E A); Forest Research Institute; Geoff Tovey Associates; GlaxoSmithKline; Glenmark Pharmaceutials; Grunenthal; GSK; Helsinki University Central Hospital; Imperial College; Imperial School Of Medicine London; MedPartners; N A P P Pharmaceutical; National Heart and Lung Institute Imperial College; National Heart and Lung Institute Imperial College London; nSpire Health Ltd; Oxagen Ltd; Prosonix Ltd; Pulmagen Therapeutics; Revotar Biopharmaceuticals; Teva UK Limited; Teva UK Ltd; UCB-Celltech; University College London; University of Groningen University Medical Centre Groningen Centre for Medical Biomics; Vectura; Vitalograph;

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College

9:10 The problem of steroid resistance in asthma and COPD

Peter Barnes

Peter Barnes, Head of Respiratory Medicine, Imperial College

 

  • Corticosteroid resistance is a major barrier to effective treatment of severe asthma and COPD 
  • The molecular mechanisms of corticosteroid resistance are now much better defined
  • This understanding identifies new therapeutic targets that may lead to reversal of steroid resistance
  • Several existing and new drugs are being developed for reversing steroid resistance in asthma and COPD
  • 9:50 Patient stratification in the development of biologicals

    Matthew Catley

    Matthew Catley, Team Leader, AstraZeneca

     

  • Asthma patient phenotypes
  • Periostin and anti-IL-13
  • Mepolizumab
  • Mechanistic endotyopes
  • 10:30 Morning Coffee

    11:00 CRTH2 antagonists: basic biology and clinical effects

    Roy Pettipher

    Roy Pettipher, Director of Pharmacology, Oxagen Ltd

     

  • Role of CRTH2 in mediating allergic disease
  • Pharmacological profile of the CRTH2 antagonist OC000459
  • Clinical effects of OC000459 in asthma and allergic rhinoconjunctivitis
  • 11:40 Innovative approaches to developing preclinical models for COPD and asthma

    Christopher  Stevenson

    Christopher Stevenson, Research Leader, Hoffmann-La Roche

     

  • Insights gained from careful characterisations of preclinical models
  • Novel bioinformatics methods for comparing preclinical models to clinical samples
  • The importance for routinely assessing changes in lung physiology in these preclinical models
  • 12:20 Networking Lunch

    13:40 New concepts in lung remodeling in Asthma and COPD

    Emma Hickman

    Emma Hickman, Research Investigator, Novartis

  • Replication of regulatory processes that occur in non-asthmatic individuals
  • Current and future methodologies for immunotherapy
  • Immunotherapy with Omalizumab
  • Immunotherapy for long-lasting treatment without immunosuppression or immune augmentation
  • 14:20 New controller therapies for asthma: From small molecules to monoclonal anti-bodies

    Mary Fitzgerald

    Mary Fitzgerald, Executive VP Respiratory, Pulmagen Therapeutics

  • New controller therapies for asthma; what is on the horizon?
  • CRTh2 antagonists; new controller therapies for asthma
  • Different combination approaches for asthma therapy; not just alternative ICS/LABAs
  • 15:00 Afternoon Tea

    15:30 Development of Inhaled Interferon beta for the Prevention or Attenuation of Virus Induced Asthma Exacerbations

    Phillip Monk

    Phillip Monk, Chief Scientific Officer, Synairgen Ltd

  • Inhaled IFN-β may prevent or ameliorate exacerbations following upper respiratory tract infection (URTI).
  • Phase I study with inhaled IFN-β
  • Analysis of biomarker responses in sputum with daily dosing of inhaled IFN-β
  • Phase II study with inhaled IFN-β
  • 16:10 Discovery and Development of small molecule CCR3 inhibitors for asthma and allergic rhinitis

    Kevin Bacon

    Kevin Bacon, Chief Scientific Officer, Axikin

  • Agonism of CCR3 and its role in allergic inflammation
  • Pharmacologic activity of small molecular weight inhibitors in vitro and in vivo
  • Clinical development
  • 16:50 Chairman’s Closing Remarks and Close of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Patrick Mallia

    Patrick Mallia, Honorary Clinical Senior Lecturer, Imperial College School of Medicine (N.H.L.I.)

    9:10 Comparing exacerbations of Asthma & COPD alongside treatment options

    Patrick Mallia

    Patrick Mallia, Honorary Clinical Senior Lecturer, Imperial College School of Medicine (N.H.L.I.)

     

  • Aetiology of exacerbations
  • Modelling exacerbations in mouse & man
  • Mechanisms of exacerbations
  • Treatment of exacerbations
  • 9:50 Developing preclinical models to mimic exacerbations of COPD and asthma

    Liz Hardaker

    Liz Hardaker, Investigator II, Novartis Horsham Research Centre

  • What are exacerbations of COPD and asthma?
  • Current therapies to treat COPD and asthma exacerbations
  • In vivo models that mimic aspects of COPD and asthma exacerbations
  • 10:30 Risk and control in the management of asthma

    Samantha Walker

    Samantha Walker, Executive Director, Research & Policy, Asthma Uk

     

  • What is the difference between risk and control in asthma?
  • How do we identify those at risk of an asthma attack?     
  • Helping people with asthma reduce their risk and improve asthma control      
  • Implications for asthma management    
  • 11:10 Morning Coffee

    11:30 Bacterial exacerbation of the altered lung

    Tracy  Hussell

    Tracy Hussell, Centre Director MCCIR, Manchester University

  • Asthma/COPD
  • Innate immunity
  • Anti-bacterial immunity
  • Epithelium and airway macrophages
  • 12:10 Inhaler therapies to deliver ICS

    Ewan Walters

    Ewan Walters, Medical Director, Teva UK Ltd

     

  • Role in delivering active treatments to the lung
  • Randomised Clinic al Trials (RCTs)
  • Modalities to assess PROs
  • Overcoming challenges
  • 12:50 Networking Lunch

    13:50 Exploring the many credible molecular and cellular mechanisms of COPD pathogenesis

    Donna Finch

    Donna Finch, Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune

     

  • Exacerbations- balancing pathogen recognition and inflammation
  • Emphysema- what drives lung destruction?
  • Can both be linked via mechanistic hypotheses?
  • 14:30 Pharmacodynamic Evaluation of Orally Inhaled Corticosteroids

    Geoff Down

    Geoff Down, Chief Medical Officer, Prosonix Ltd

  • Scientific and regulatory background
  • Current issues
  • Conventional and exploratory methods
  • Interpretation and evaluation
  • 15:10 Carbocysteine; New perspective on an old drug

    Simon MacKenzie

    Simon MacKenzie, Director of Product Strategy Centre, Kyorin Pharmaceutical Co Ltd

  • Historical use as a mucolytic
  • The influence of patients
  • Current recognised clinical role
  • Additional benefits being uncovered
  • 15:50 Afternoon Tea

    16:10 Asthma/COPD - phenotypes, biomarkers and implication for stratified therapeutic approaches

    Harald Renz

    Harald Renz, Head of Department of Clinical Chemistry and Molecular Diagnostics, University Of Marburg

  • Patient phenotypes
  • Application of biomarkers
  • Challenges of therapeutic approaches
  • 16:40 New strategies to target airway smooth muscle remodelling in asthma: insight from a theoretical model

    Bindi Brook

    Bindi Brook, Lecturer, University Of Nottingham

  • Theoretical mathematical model describing the growth dynamics of airway smooth muscle (ASM) cells
  • Mild and severe ASM hyperplasia explained
  • The importance of inflammation resolution speed
  • 17:20 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Christopher  Stevenson

    Christopher Stevenson

    Research Leader, Hoffmann-La Roche
    Ewan Walters

    Ewan Walters

    Medical Director, Teva UK Ltd
    Matthew Catley

    Matthew Catley

    Team Leader, AstraZeneca
    Peter Barnes

    Peter Barnes

    Head of Respiratory Medicine, Imperial College

    Bindi Brook

    Lecturer, University Of Nottingham
    Bindi Brook

    Christopher Stevenson

    Research Leader, Hoffmann-La Roche
    Christopher  Stevenson

    Donna Finch

    Principal Scientist, Respiratory, Inflammation and Autoimmunity, MedImmune
    Donna Finch

    Emma Hickman

    Research Investigator, Novartis
    Emma Hickman

    Ewan Walters

    Medical Director, Teva UK Ltd
    Ewan Walters

    Geoff Down

    Chief Medical Officer, Prosonix Ltd
    Geoff Down

    Harald Renz

    Head of Department of Clinical Chemistry and Molecular Diagnostics, University Of Marburg
    Harald Renz

    Kevin Bacon

    Chief Scientific Officer, Axikin
    Kevin Bacon

    Kevin Bacon

    Chief Scientific Officer, Axikin
    Kevin Bacon

    Liz Hardaker

    Investigator II, Novartis Horsham Research Centre
    Liz Hardaker

    Mary Fitzgerald

    Executive VP Respiratory, Pulmagen Therapeutics
    Mary Fitzgerald

    Matthew Catley

    Team Leader, AstraZeneca
    Matthew Catley

    Patrick Mallia

    Honorary Clinical Senior Lecturer, Imperial College School of Medicine (N.H.L.I.)
    Patrick Mallia

    Peter Barnes

    Head of Respiratory Medicine, Imperial College
    Peter Barnes

    Phillip Monk

    Chief Scientific Officer, Synairgen Ltd
    Phillip Monk

    Roy Pettipher

    Director of Pharmacology, Oxagen Ltd
    Roy Pettipher

    Samantha Walker

    Executive Director, Research & Policy, Asthma Uk
    Samantha Walker

    Simon MacKenzie

    Director of Product Strategy Centre, Kyorin Pharmaceutical Co Ltd
    Simon MacKenzie

    Tracy Hussell

    Centre Director MCCIR, Manchester University
    Tracy  Hussell

    Workshops

    Clinical Trial Design in Asthma & COPD
    Workshop

    Clinical Trial Design in Asthma & COPD

    Copthorne Tara Hotel
    17th April 2013
    London, United Kingdom

    Copthorne Tara Hotel

    Scarsdale Place
    Kensington
    London W8 5SR
    United Kingdom

    Copthorne Tara Hotel

    The Copthorne Tara Hotel London Kensington is an elegant contemporary four-star hotel in prestigious Kensington, located just a two minutes walk from High Street Kensington underground station, making exploring easy. The hotel offers well-appointed and comfortable guest rooms combining Standard, Superior and Club accommodation. Club rooms offer iconic views over the city and include Club Lounge access for complimentary breakfast and refreshments. Guests can sample the authentic Singaporean, Malaysian and Chinese cuisine at Bugis Street, traditional pub fare at the Brasserie Restaurant & Bar or relax with a delicious drink at West8 Cocktail Lounge & Bar.

    The Copthorne Tara Hotel boasts 745 square meters of flexible meeting space, consisting of the Shannon Suite and the Liffey Suite, ideal for hosting conferences, weddings and social events. Facilities include access to the business centre 24 hours a day, fully equipped fitness room, gift shop, theatre desk and Bureau de Change. With ample onsite parking outside the London congestion charge zone and excellent transport links via Heathrow Airport, the hotel is the perfect location for business or leisure stays. The hotel is within close proximity to the shops of High Street Kensington, Knightsbridge and Westfield London, Olympia Conference Centre, Royal Albert Hall, Kensington Palace and Hyde Park.

     

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.